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Patients with chronic kidney disease (CKD) have a high risk of
hyperkalemia, which increases mortality and can lead to
renin–angiotensin–aldosterone system inhibitor (RAASi) dose
reduction or discontinuation. Patiromer, a nonabsorbed
potassium binder, has been shown to normalize serum
potassium in patients with CKD and hyperkalemia on RAASi.
Here, patiromer’s onset of action was determined in patients
with CKD and hyperkalemia taking at least one RAASi. After a
3-day potassium- and sodium-restricted diet in an inpatient
research unit, those with sustained hyperkalemia (serum
potassium 5.5 – under 6.5mEq/l) received patiromer 8.4 g/
dose with morning and evening meals for a total of four
doses. Serum potassium was assessed at baseline (0 h), 4 h
postdose, then every 2–4 h to 48 h, at 58 h, and during
outpatient follow-up. Mean baseline serum potassium was
5.93mEq/l and was significantly reduced by 7 h after the first
dose and at all subsequent times through 48 h. Significantly,
mean serum potassium under 5.5mEq/l was achieved within
20 h. At 48 h (14 h after last dose), there was a significant
mean reduction of 0.75mEq/l. Serum potassium did not
increase before the next dose or for 24 h after the last dose.
Patiromer was well tolerated, without serious adverse events
and no withdrawals. The most common gastrointestinal
adverse event was mild constipation in two patients. No
hypokalemia (serum potassium under 3.5mEq/l) was
observed. Thus, patiromer induced an early and sustained
reduction in serum potassium and was well tolerated in
patients with CKD and sustained hyperkalemia on RAASis.
Kidney International (2015) 88, 1427–1433; doi:10.1038/ki.2015.270;
published online 16 September 2015
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Hyperkalemia may induce lethal cardiac arrhythmias.1
Patients with chronic kidney disease (CKD), especially when
treated with inhibitors of the renin–angiotensin–aldosterone
system (RAAS), have a high risk of hyperkalemia.1–5
Treatment of severe hyperkalemia involves pharmacologic
stabilization of the cardiac membranes, moving potassium
into cells, and finally removal of potassium from the body.6
With impaired renal function, removal of body potassium is
limited to dialysis or augmentation of gastrointestinal
potassium excretion.6
Sodium polystyrene sulfonate and calcium polystyrene
sulfonate have been utilized to increase fecal potassium
excretion; however, despite their long history of clinical use,
there is little evidence from prospective clinical trials demon-
strating their efficacy; moreover, they may cause serious, life-
threatening gastrointestinal adverse effects.7–12 The serious
gastrointestinal adverse events, in combination with milder
adverse reactions, including poor palatability, make these agents
difficult for patients to tolerate, thereby limiting their utility in
chronic care settings.4 As a consequence of the limitations to the
use of medicines in chronically hyperkalemic individuals,
clinicians frequently face the dilemma of reducing the dose
of, or discontinuing, their patients’ RAAS inhibitors (RAASis) in
order to manage serum potassium elevations.3,5 In doing so,
the physician is often forced to choose between the established
benefit of RAASis in patients with CKD and the avoidance of a
potentially life-threatening hyperkalemic complication.
Patiromer for oral suspension is under investigation for the
treatment of hyperkalemia. The active moiety, patiromer, is a
nonabsorbed polymer that binds potassium in the gastro-
intestinal tract, leading to an increase in fecal potassium
excretion and a decrease in serum potassium.13,14 Patiromer
consists of smooth, spherical beads ~ 100 μm in diameter that
are free-flowing and do not swell appreciably when placed in
liquids.13
Prior studies of patiromer have focused on its efficacy,
safety, and tolerability in the treatment of hyperkalemic
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patients in studies that have ranged from 12 to 52 weeks in
duration.13–16 In those studies, the earliest time point at which
the drug’s effect on potassium was routinely measured was
48 h after the initial dose, by which time significant serum
potassium reductions were seen. The impact of patiromer on
serum potassium levels before 48 h was unknown. The purpose
of this study was to characterize the onset-of-action of
patiromer’s potassium lowering activity in the interval between
the initial dose and 48 h postdose. To accomplish this goal,
hyperkalemic CKD patients taking at least one RAASi were
admitted to an inpatient clinical research unit (CRU), entered a
3-day diet run-in, were treated with patiromer, and the
patients’ changes in serum potassium levels were documented
at frequent intervals over the course of the next 3 days.
RESULTS
A total of 29 patients were screened (Figure 1). Twenty-seven
patients met the eligibility criteria and were enrolled, entering
the potassium- and sodium-restricted diet run-in phase. Two
patients were withdrawn during run-in because they met
protocol-specified withdrawal criteria (in both cases, serum
potassium o5.5 mEq/l at the end of run-in). The remaining
25 patients had a sustained, elevated serum potassium during
the run-in phase (Figure 2). These patients then entered the
treatment phase, completed treatment with patiromer
(4 doses over 2 days), and attended all follow-up visits. The
study population was predominantly male, with a mean age of
58.7 years (Table 1). The majority had moderate-to-severe
CKD as determined by the central laboratory. All patients
were receiving at least one RAASi.
Efficacy
The study achieved its primary objective and found a
significant reduction in serum potassium at 7 h after the first
dose of patiromer (Figure 2). From a mean (s.e.) baseline
serum potassium of 5.93 (0.04) mEq/l, a significant reduction
in serum potassium of 0.21 (0.07) mEq/l (95% confidence
interval (CI)=− 0.35, − 0.07, P= 0.004) occurred 7 h after the
first patiromer dose. The median (quartiles 25%, 75%) serum
potassium was 5.90 (5.85, 6.05) at baseline, with a reduction
in serum potassium of 0.20 (−0.3, − 0.10) mEq/l at 7 h.
Significant reductions occurred at all assessments from
7–48 h (Pp 0.004 at 7 h and 10 h; Po0.001 for 12–48 h).
Mean serum potassium decreased to 5.41 mEq/l by 20 h after
the first patiromer dose (Po0.001), with a median serum
potassium of 5.50 (5.20, 5.60) mEq/l. At 48 h (14 h after the
last dose), a 0.75 (0.07) mEq/l mean reduction (95% CI=
− 0.89, − 0.61, Po0.001), and a 0.65 (−0.95, − 0.35) mEq/l
median reduction from baseline were observed. Mean and
median serum potassium did not increase before the next dose
of patiromer.
Mean (s.e.) and median (25%, 75%) serum potassium at
the time of the last patiromer dose (34 h) were 5.28 (0.06) and
5.37 (5.00, 5.60) mEq/l, respectively, and continued to
decline, with significant (Po0.001) mean reductions from
baseline observed from the last dose to the 38-, 41-, 44-, and
48-h time points. At 58 h (24 h after the last dose), the mean
and median serum potassium were 5.27 (0.11) and 5.40 (5.10,
5.60), respectively, and the mean was not significantly
different from the level at the time of the last patiromer dose
(34 h). Five days after the first dose (~86 h after the last dose),
mean (s.e.) serum potassium increased significantly from 34 h
by 0.27 (0.05) mEq/l (95% CI= 0.17, 0.36) to 5.55 (0.05)
mEq/l, and the median serum potassium increased to 5.60
(5.40, 5.70) mEq/l. Eight days after the first dose (~158 h after
the last dose), mean serum potassium increased significantly
from 34 h by 0.48 (0.05) mEq/l (95% CI= 0.38, 0.58) to 5.76
(0.05) mEq/l, and the median serum potassium increased to
5.80 (5.60, 5.90) mEq/l.
Seventeen patients had moderate hyperkalemia at baseline
(mean (s.e.)= 5.84 (0.03)mEq/l); eight patients had severe
hyperkalemia (mean (s.e.)= 6.14 (0.04) mEq/l). In a prespeci-
fied secondary analysis, mean changes in serum potassium over
time in these two subgroups were consistent with those seen in
the overall population. For patients with moderate and severe
hyperkalemia, respectively, the mean (s.e.) change from baseline
at 7 h was − 0.17 (0.07)mEq/l (95% CI=− 0.31, − 0.03)
and − 0.29 (0.15)mEq/l (95% CI=− 0.61, 0.04), respectively.
In a prespecified exploratory analysis, the proportion of
patients with serum potassium values p 5.5mEq/l was 20%,
36%, and 80% at 7-, 12-, and 24- h, respectively (Figure 3). In a
post hoc analysis, the median time to achieve first serum
potassium p 5.5mEq/l was 12.7 h (95% CI=11.0, 22.6;
Figure 4).
Safety
Patiromer was well tolerated over 2 days of treatment, with no
serious or severe adverse events reported. Seven (28%)
patients experienced eight adverse events during the active
treatment phase through follow-up. The most common
adverse events (occurring in two patients each) were mild
constipation and mild hypotension (Table 2). No deaths
occurred in the study, and no adverse events led to study drug
withdrawal. No hypokalemic events (serum potassium o3.5
mEq/l) or hypomagnesemia (o1.4 mg/dl) were reported, and
Assessed for eligibility
(N = 29)
Excluded (n = 2)
Run-in failures (n = 2)
• Serum K+ not in range of
5.5 to <6.5 mEq/l
• Met protocol-specified
withdrawal criteria based
on serum K+ results
Enrolled (n = 27)
Completed controlled diet
run-in (n = 25)
Received patiromer 8.4 g
BID for 2 days (n = 25)
Completed treatment and
follow-up phase (n = 25)
Figure 1 |Patient disposition. BID, twice daily; K+, potassium.
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no clinically relevant alterations in other blood chemistry
parameters were observed. Two patients (8%) experienced an
increase from baseline in serum magnesiumX 0.4 mg/dl, and
no patient had a decrease of X 0.4 mg/dl.
No patients had electrocardiogram (ECG) changes that
were consistent with hypokalemia or hyperkalemia during
active treatment through follow-up. There were no clinically
relevant changes in vital signs by criteria prespecified in the
protocol.
DISCUSSION
This study was designed to evaluate the onset-of-action of
patiromer in representative patients with sustained hyperka-
lemia in the controlled environment of a CRU. We
demonstrate that, after a single dose of patiromer, there was
a significant reduction in mean serum potassium by 7 h in
moderate-to-severe hyperkalemic CKD patients receiving at
least one RAASi while consuming a 60mEq/day potassium
diet. Mean serum potassium continued to decrease and after a
second dose of patiromer fell too5.5mEq/l by 20 h. By 24 h,
more than 80% of patients had a serum potassium
p 5.5 mEq/l. At 48 h, after four doses of patiromer, mean
serum potassium had fallen by 0.75mEq/l, and more than 90%
of patients had serum potassium valuesp 5.5 mEq/l. Over the
entire study, mean serum potassium did not increase before the
next dose of patiromer. After the last dose of patiromer was
administered at 34 h, mean serum potassium was 5.28mEq/l.
Mean serum potassium did not increase for the next 24 h and
was 5.27mEq/l at 58 h. However, mean serum potassium
increased significantly at ~ 86 and 158 h after the last dose of
patiromer. No patient developed hypokalemia, and patiromer
was well tolerated with only mild adverse events.
The most common risk factors for hyperkalemia include
the presence of CKD, diabetes mellitus, myocardial dysfunc-
tion, and the use of RAASis.17,18 Thus, the study population
was representative of patients who commonly present with
hyperkalemia, as reflected by their baseline characteristics
(i.e., 88% had estimated glomerular filtration rate o60 ml/
min per 1.73 m2, 60% had diabetes mellitus, 28% had heart
failure, all had hypertension, and all were on RAASis).
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Table 1 |Baseline demographics and clinical characteristics
Characteristic Patiromer 16.8 g/day, N=25
Age, years—mean (s.d.) 58.7 (12.3)
Male—No. (%) 15 (60)
Caucasian—No. (%) 25 (100)
Body mass index, kg/m2—mean (s.d.) 27.9 (3.9)
Type II diabetes mellitus—No. (%) 15 (60)
Hypertension—No. (%) 25 (100)
History of MI—No. (%) 4 (16)
History of heart failure—No. (%) 7 (28)
Duration of CKD, years—mean (s.d.) 4.49 (4)
eGFR, ml/min per 1.73m2—mean (s.d.) 34.8 (20.7)
CKD stagea—No. (%)
X 90ml/min per 1.73m2 1 (4)
60–89ml/min per 1.73m2 2 (8)
30–59ml/min per 1.73m2 9 (36)
15–29ml/min per 1.73m2 11 (44)
o15ml/min per 1.73m2 2 (8)
Serum potassium,b mEq/l—mean (s.d.) 5.93 (0.18)
Serum potassium 46.0mEq/l—No. (%) 8 (32)
On a RAASi—No. (%) 25 (100)
Diuretic—No. (%) 11 (44)
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration
rate; MI, myocardial infarction; RAASi, renin–angiotensin–aldosterone system
inhibitor; s.d., standard deviation.
aStage 1 (normal): X 90ml/min per 1.73m2; Stage 2 (mild): 60–89ml/min per
1.73m2; Stage 3 (moderate): 30–59ml/min per 1.73m2; Stage 4 (severe): 15–29ml/
min per 1.73m2; Stage 5 (end-stage): o15ml/min per 1.73m2.
bAverage of two central laboratory serum potassium values from samples collected
at hour − 1 and 0 on treatment day 1.
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Moreover, patients were on a potassium- and sodium-
restricted diet during the inpatient phase of the study and
were counseled to follow a low-potassium diet during the
outpatient phase, similar to what is recommended for most
patients who are at risk of hyperkalemia.19
In this study, eight adverse events were reported in seven
patients. The most common side effects were mild constipa-
tion and mild hypotension, each occurring in two patients.
There were no serious side effects and no side effects that led
to a change in study drug dose or its discontinuation.
Patiromer has previously been reported to safely and
effectively lower serum potassium and maintain normokale-
mia in several controlled trials,14–16 involving a total of 603
patients on active treatment. The need for chronic therapy
with patiromer was demonstrated by the significant increase
in serum potassium after discontinuation of patiromer in the
AMETHYST-DN study.16 In the current study, a significant
increase in mean serum potassium 4 and 7 days after the last
dose of patiromer was also observed.
The strength of the efficacy findings derives from the study’s
rigorous design, including the inpatient treatment phase and
enrollment of patients with persistent hyperkalemia while on a
stable, potassium- and sodium-restricted diet. These design
elements are optimal for determining the early onset effects of a
drug on serum potassium. The 3‐day run-in ensured the
identification of patients with chronic or persistent hyperkale-
mia and also that patients with spurious (i.e., due to hemolysis),
transient, and/or postprandial hyperkalemia were excluded.20
In addition, as serum potassium may vary secondary to diurnal
variation21 and fasting/feeding cycles,22 serum potassium was
recorded at prespecified intervals for 72 h, in the run-in period
designed to confirm chronic hyperkalemia, reduce serum
potassium variation, and establish a stable baseline serum
potassium before treatment with patiromer.
Whether potassium would have decreased more rapidly or
to a greater extent with a larger initial dose of patiromer or a
different dosing regimen (e.g., 3 times daily dosing) cannot be
determined from the data presented here. In the current
study, the dose of patiromer was not titrated to the level of
serum potassium. The total daily dose was lower than the
mean 21.4 g daily that was used over the first 4 weeks in the
phase 3 study in patients with moderate-to-severe
hyperkalemia.14 Whether patiromer, as an adjunct to
conventional therapy, will help lower potassium more rapidly
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Table 2 |Adverse events
Adverse event category Patiromer 16.8 g/day, N=25
Patients with at least one AE, No. (%) 7 (28)
Serious 0
Resulting in death 0
Leading to study drug discontinuation 0
Resulting in a change of dose 0
Related to patiromer 3 (12)
Severe 0
Most common 3 (12)
Constipation (mild) 2 (8)
Hypotension (mild) 2 (8)
Abbreviation: AE, adverse event.
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in the emergency setting of acute life-threatening hyperkale-
mia remains to be evaluated.
Limitations of the study include the lack of a placebo
control. All patients in this study had sustained, significantly
elevated serum potassium levels (X5.5 mEq/l) for 3 days
before the initiation of patiromer treatment. The significant
reductions in serum potassium in this study are unlikely to
have occurred without patiromer, given the stability of serum
potassium values observed during the potassium- and
sodium-restricted dietary run-in phase leading up to study
qualification and enrollment, the use of a separate blood
sample for assessment of baseline serum potassium, and the
significant increase in serum potassium at ~ 86 and 158 h
after the last dose of patiromer. The use of an active control
such as sodium polystyrene sulfonate, the only drug
specifically indicated for the treatment of hyperkalemia in
the United States, was also considered but was felt to be
inappropriate because of the lack of prospective, controlled
trials demonstrating the efficacy of this agent, its potential to
cause intestinal necrosis as detailed in the prescribing
information,23 and its poor gastrointestinal tolerability
making blinding difficult.8–12,24–32
In conclusion, patiromer induced an early and a sustained,
clinically significant reduction in serum potassium in
moderately and severely hyperkalemic patients with CKD
who were taking RAASis. After the first significant decrease in
mean serum potassium at 7 h, mean serum potassium levels
continued to decrease, never increasing before the next dose or
for 24 h after the last dose of patiromer. Patiromer did not
induce hypokalemia, and it was well tolerated.
MATERIALS AND METHODS
Design overview
This phase 1, open-label, single-arm study was designed to evaluate
the onset of effect of patiromer in patients with hyperkalemia and
CKD who were receiving at least one RAASi. The study was
conducted at CRUs and included an inpatient potassium- and
sodium-restricted diet run-in and treatment phases and inpatient
and outpatient follow-up phases (Figure 5).
Study organization
The study was conducted at five sites in Europe. Relypsa, Inc.
(Redwood City, CA, USA), sponsored the study; Worldwide Clinical
Trials provided medical, safety, and site monitoring; and PAREXEL
International provided overall study management, site monitoring,
and data management. Statistical analyses were performed by
PharmaStat, LLC (Newark, CA). ECGs were read at a core ECG
laboratory, and an independent safety review board adjudicated all
potassium-related ECG changes identified by the core laboratory.
The protocol and informed consent forms were approved by the
independent ethics committees for each participating site, and all
patients provided written informed consent. The study was
conducted in accordance with the International Conference for
Harmonization Good Clinical Practice guidelines and local and
national regulations.
Patient population
Patients aged 18–80 years with estimated glomerular filtration rate 15
to o90ml/min per 1.73 m2 and serum potassium 5.5–6.2mEq/l at
screening were eligible to enter the run-in phase. Patients were
required to be on a stable dose of at least one RAASi medication for
28 days before screening and, if taking antihypertensive medications
(including diuretics and β-blockers), on a stable dose of those
medications for at least 14 days before screening. Exclusion criteria
included potassium-related ECG changes at screening, insulin-
dependent or uncontrolled diabetes, severe swallowing disorder,
moderate-to-severe gastroparesis, or a history of bariatric surgery,
uncontrolled hypertension, significant (dialysis, transplant, acute
injury, autoimmune) kidney disease, or major cardiovascular event
within 2 months before screening. Use of potassium supplements,
bicarbonate, or baking soda was not allowed in the 7 days before
screening or during the study.
Procedures
Eligible patients were admitted to a CRU and began a 3-day
controlled metabolic diet (potassium 60mEq/day and sodium 100
mEq/day) run-in phase. The controlled diet continued throughout
the 6-day inpatient stay (Figure 5). Serum potassium was assessed
twice daily (i.e., every 10–14 h) during the run-in phase; a separate
blood sample was drawn for the assessment of serum potassium at
baseline. Assessments of serum potassium were performed by both
the local and central laboratory. Local laboratory measurements were
used for assessments of study inclusion criteria and for testing related
to the clinical care of patients. Central laboratory measurements were
used for assessments of baseline values and efficacy and safety; all
samples were tested for evidence of hemolysis using a validated,
semiquantitative method. Patients were withdrawn from the study at
any time during the controlled diet run-in if serum potassium was
X 6.5 mEq/l, increased by40.5 mEq/l from screening, or decreased
by 40.3 mEq/l within the final 15 h of the diet run-in phase.
At the end of the run-in, patients with serum potassium 5.5 to
o6.5 mEq/l entered the treatment phase and began patiromer 8.4 g
twice daily with meals for 2 days, for a total of four doses (i.e., at
baseline (time 0) and 10, 24, and 34 h after the first dose). All
patients received the same amount of patiromer regardless of their
serum potassium. Serum potassium was assessed 1 h before
treatment, at baseline just before treatment (time 0), and 4, 7, 10,
12, 14, 17, 20, 24, 28, 31, 34, 36, 38, 41, 44, 48, and 58 h after the first
patiromer dose. Patients were discharged from the CRU at 58 h and
were instructed to remain on a low-potassium diet (~50–75 mEq/
CRU
admission
Diet run-in
3 days (n = 27)†
Treatment period
8.4 g patiromer BID
2 days (n = 25)
Patiromer given
at 0, 10, 24,
and 34 h Discharged from CRU to
outpatient follow-up
Instructed to
follow low K+ diet
Post-treatment
outpatient follow-up
6 days (n = 25)
Post-treatment
follow-up in CRU
1 day (n = 25)
Run-in failure (n = 2)
K+ not in range of 5.5
to <6.5 mEq/l
Primary end point
assessed at 48 h*
Controlled diet in CRU
(K+ 60 mEq/d, Na+ 100 mEq/day)
Figure 5 | Study design. *A sequential testing procedure was used to
determine the earliest time point at which the change from baseline in
serum potassium was significant. Starting at 48 h, each time point was
tested in order of reverse chronology (i.e., 48, 44, 41, 38 h, etc.), with the
preceding time point assessed only if the change from baseline in
serum potassium for the previously examined time point was
statistically significantly. †Patients with serum potassium 5.5 to
o6.5mEq/l after the 3-day low-potassium, low-sodium diet run-in
entered the treatment phase. BID, twice daily; CRU, clinical research unit;
K+, potassium; Na+, sodium.
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day) during the post-discharge outpatient follow-up phase. Post-
discharge follow-up assessments, including serum potassium, were
performed on 5 and 8 days after the first dose (i.e., study days 9 and
12). Adverse events were collected throughout the inpatient
phase and at each outpatient follow-up visit. Vital signs, 12-lead
ECGs, and blood samples for serum chemistry and hematology
were measured at various intervals throughout the study. High
potassium values that, in the opinion of the investigator, warranted
immediate treatment could be managed according to the local
standard of care.
End points
The primary end point was the change in serum potassium from
baseline during the 48 h after the first dose. The time of onset for
patiromer was defined as the earliest time point at which the mean
change in potassium from baseline was significant o0 mEq/l
(Po0.05). The secondary end point was the change in serum
potassium from baseline in prespecified subgroups defined by
severity of hyperkalemia at baseline: moderate (serum potassium
5.5–6.0 mEq/l) and severe hyperkalemia (serum potassium 46.0–
6.5 mEq/l).The proportion of patients achieving normokalemia
(serum potassium 3.5–5.0 mEq/l) was a prespecified exploratory
end point. An ad hoc exploratory analysis was conducted to evaluate
the change in serum potassium from the last dose of patiromer and a
post hoc analysis evaluated the time to first serum potassium
p 5.5 mEq/l. Adverse events that occurred through the post-
treatment follow-up phase are summarized descriptively.
Statistical analysis
The expected population mean (s.d.) change in serum potassium
from baseline was − 0.3 (0.473) mEq/l based on data from previous
patiromer studies. Using a one group t-test, two-sided at a
significance level of 0.05, it was estimated that a total of 22 patients
were needed to provide 80% power to detect a mean change in
serum potassium from baseline of − 0.3 mEq/l.
All patients were included in the analyses who received at least
one dose of patiromer and had baseline and at least one post-baseline
serum potassium measurement. The least squares mean, standard
error (s.e.), and two-sided 95% CIs for the change from baseline in
serum potassium were calculated for each post-first dose time point
through 48 h. The primary end point was evaluated using a mixed-
effect model repeated measures analysis, with change from baseline
in serum potassium as the dependent variable, time point as a fixed
effect, and patient as a random effect. A sequential testing
procedure was used to account for multiple comparisons of the
primary end point,33 conducted from the latest to the earliest time
points after the first patiromer dose (i.e., 48, 44, 41, 38, 36,
34, 31, 28, 24, 20, 17, 14, 12, 10, 7, and 4 h). Each subsequent time
point was assessed only if all the changes in serum potassium from
baseline were significantly o0 mEq/l (two-sided Po0.05) for all
previously examined time points. For the secondary analysis, a
longitudinal mixed-effect repeated measures model was used, similar
to the primary analysis. The time to first reduction in serum
potassium to p 5.5 mEq/l was assessed by the Kaplan–Meier
method. Serum potassium values are presented as least squares
mean (s.e.), mean (s.d.), and/or median (quartiles 25%, 75%), and
change from baseline or change from last dose in serum potassium
values are presented as least squares mean (s.e.), and/or median
(quartiles 25%, 75%).
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